Welcome to our dedicated page for IMA news (Ticker: IMA), a resource for investors and traders seeking the latest updates and insights on IMA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect IMA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of IMA's position in the market.
ImageneBio, Inc. (NASDAQ: IMA) has completed its merger with Ikena Oncology, combining their operations with a concurrent $75 million private placement from investors including Deep Track Capital, Foresite Capital, and RTW Investments. The merged entity will begin trading on July 28, 2025, under the ticker symbol "IMA".
The transaction includes a 1-for-12 reverse stock split of Ikena's common stock. Post-merger ownership structure comprises 43.1% Inmagene legacy holders, 35.3% Ikena legacy holders, and 21.6% new investors, with approximately 11.6 million shares outstanding. The company, led by CEO Dr. Kristin Yarema, will continue developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, with Phase 2b topline data in atopic dermatitis expected in Q4 2026.
